Monte Rosa Therapeutics, Inc.
GLUE
$4.59
-$0.23-4.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 177.99M | 159.49M | 75.62M | 14.98M | 5.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 177.99M | 159.49M | 75.62M | 14.98M | 5.76M |
| Cost of Revenue | 121.44M | 118.06M | 112.86M | 101.57M | 102.38M |
| Gross Profit | 56.55M | 41.43M | -37.24M | -86.60M | -96.62M |
| SG&A Expenses | 41.59M | 43.56M | 43.87M | 42.38M | 42.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 163.03M | 161.62M | 156.73M | 143.95M | 145.18M |
| Operating Income | 14.96M | -2.13M | -81.11M | -128.98M | -139.42M |
| Income Before Tax | 28.42M | 9.46M | -70.13M | -119.01M | -129.93M |
| Income Tax Expenses | 4.26M | 3.31M | 2.57M | 384.00K | 483.00K |
| Earnings from Continuing Operations | 24.17 | 6.15 | -72.70 | -119.39 | -130.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.17M | 6.15M | -72.70M | -119.39M | -130.41M |
| EBIT | 14.96M | -2.13M | -81.11M | -128.98M | -139.42M |
| EBITDA | 23.30M | 6.14M | -72.99M | -121.07M | -131.78M |
| EPS Basic | 0.29 | 0.02 | -1.08 | -1.83 | -2.24 |
| Normalized Basic EPS | 0.22 | 0.04 | -0.66 | -1.14 | -1.40 |
| EPS Diluted | 0.29 | 0.01 | -1.09 | -1.84 | -2.25 |
| Normalized Diluted EPS | 0.21 | 0.03 | -0.66 | -1.14 | -1.40 |
| Average Basic Shares Outstanding | 328.47M | 317.51M | 295.52M | 270.33M | 238.13M |
| Average Diluted Shares Outstanding | 329.27M | 318.32M | 295.52M | 270.33M | 238.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |